Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $29.25 Consensus Target Price from Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have earned a consensus rating of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $29.25.

EYPT has been the subject of a number of analyst reports. TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Royal Bank Of Canada lifted their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th.

Eyepoint Pharmaceuticals Trading Up 4.3%

NASDAQ:EYPT opened at $15.33 on Monday. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $19.11. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -5.13 and a beta of 1.76. The business’s 50-day moving average price is $15.72 and its two-hundred day moving average price is $13.89.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 42,544 shares of Eyepoint Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $17.10, for a total transaction of $727,502.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Cyndeo Wealth Partners LLC increased its position in shares of Eyepoint Pharmaceuticals by 3.4% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock worth $420,000 after acquiring an additional 760 shares in the last quarter. California State Teachers Retirement System boosted its stake in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the period. RWC Asset Management LLP increased its holdings in Eyepoint Pharmaceuticals by 6.4% during the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after purchasing an additional 1,040 shares in the last quarter. MCF Advisors LLC raised its stake in shares of Eyepoint Pharmaceuticals by 8.3% in the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after purchasing an additional 1,149 shares during the period. Finally, Raymond James Financial Inc. lifted its holdings in shares of Eyepoint Pharmaceuticals by 11.0% in the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.